Skip to main content
. 2018 Feb 2;36(10):942–950. doi: 10.1200/JCO.2017.77.3994

Fig 5.

Fig 5.

Best overall response (BOR) and progression-free survival (PFS) by major histocompatibility complex (MHC) class II expression. Total number of evaluable patients for MHC class II expression was 72. Three cases were not evaluable for BOR in A (n = 69). All 72 patients were evaluable for PFS in B and C. (A) BOR by MHC class II expression. For each category of expression, the No. (%) of patients with each BOR are indicated. (B) PFS by MHC class II expression in patients who underwent autologous stem-cell transplantation ≤ 12 months before nivolumab treatment (n = 22; P = .16, log-rank test). (C) PFS by MHC class II expression in patients who underwent autologous stem-cell transplantation > 12 months before nivolumab treatment (n = 50; P = .014, log-rank test). CR, complete remission; Dec, decreased; Neg, negative; PD, progressive disease; PD-1, programmed death 1; Pos, positive; PR, partial remission; SD, stable disease.